PROTIA INC. Logo

PROTIA INC.

Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.

303360 | KO

Overview

Corporate Details

ISIN(s):
KR7303360002
LEI:
Country:
South Korea
Address:
서울특별시 강서구 양천로 401, 강서한강자이타워 A동 702호, 강서구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PROTIA INC. is an in vitro diagnostics (IVD) company that designs, develops, and manufactures a wide range of diagnostic kits and instruments. Leveraging patented technologies and proteomics-based biomarker research, the company offers solutions across multiple medical fields, including allergy, point-of-care testing (POCT), infectious diseases, autoimmune disorders, cancer, and animal diagnostics. PROTIA is particularly recognized for its high-performance multiplex allergy diagnostic kits, such as the PROTIA Allergy-Q series. The company also developed the world's first total IgG quantitative POCT kit using whole blood. In addition to its products, PROTIA provides specialized protein analysis and custom research services, including protein identification, characterization, and rapid kit development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-12 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-07-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-07-18 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.5 KB
2025-05-09 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.4 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 18.4 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.3 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 170.9 KB
2025-02-24 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.9 KB
2025-01-24 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB
2025-01-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 188.1 KB

Automate Your Workflow. Get a real-time feed of all PROTIA INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PROTIA INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PROTIA INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO

Talk to a Data Expert

Have a question? We'll get back to you promptly.